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Inactivation of p53 gene in human and murine osteosarcoma cells
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Summary We examined structure and expression of the p53 and Rb genes in a C3HOS transplantable mouse
model of osteosarcoma. The results were compared to analogous studies conducted with five human osteosar-
coma cell lines. The p53 gene was found rearranged in the mouse tumour. The rearrangement mapped to the
first intron region of the p53 gene and as a result, no p53 expression could be detected in C3HOS tumours.
Using p53 genomic probes, we have detected the same rearrangement in the original radiation-induced tumour
and the various clones that were isolated from it. Deletion and rearrangement of the p53 gene were also found
in three out of five of the human osteosarcoma cell lines (MG-63, G-292, Saos-2). No p53 expression could be
detected in these three cell lines. In the affected human osteosarcoma cell lines, the rearrangement involved the
first intron region. In addition, the mouse tumour was analysed for structural and expression changes in the
Rb and the c-myc genes. Normal expression of both genes were detected in the murine tumour. Only one
(Saos-2) human osteosarcoma cell line exhibited gross structural alteration in the retinoblastoma gene. The
results suggest that the inactivation of p53 may be an important step in the development of osteosarcomas,
and that a rearrangement affecting the first intron is common in osteosarcomas.
Cytogenetic investigations of human osteosarcoma reveal a
variety of chromosomal abnormalities, some of which are
presumed to have a direct relationship to the disease (Gilman
et al., 1985). A frequent loss of heterozygosity has been
localised on specific regions of chromosomes 17 (Toguchida
et al., 1988) and 13 (Toguchida et al., 1989). In both cases,
the deleted chromosomal loci involve tumour suppressor
genes, the retinoblastoma gene on chromosome 13 (Friend et
al., 1987) and the p53 on chromosome 17 (Miller et al.,
1986).
The retinoblastoma gene (Rb) was first identified as a
tumour suppressor gene, as it was found inactivated in both
sporadic and familial retinoblastoma tumours (Friend et al.,
1987; Lee et al., 1987; Hansen et al., 1985. Subsequently the
Rb gene was found to be inactivated in a number of other
tumours (Lee et al., 1988; Harbour et al., 1988), including
osteosarcomas that arose either as primary or secondary
tumours (Dryja et al., 1986; Reissmann et al., 1989). The p53
gene was originally considered a dominant oncogene, but
several lines of evidence have established that the wild-type
gene product actually functions as a tumour suppressor (Fin-
lay et al., 1989; Eliyahu et al., 1989). Like the Rb gene, the
p53 gene is implicated in the pathogenesis of various human
malignancies through loss of function mutations (Baker et
al., 1989; Nigro et al., 1989). It was previously reported that
primary osteosarcoma lacks a functional p53 gene (Masuda
et al., 1987; Miller et al., 1990).
Many of the animal models of osteosarcoma are poor
representatives of the human disease. The cell lines derived
from human, as well as animal osteosarcomas rarely produce
tumours upon injection into immunodeficient or syngeneic
animals. Thus, most of the information on tumour suppres-
sor genes in osteosarcoma has been derived from surgical
specimens of human osteosarcomas and established osteosar-
coma cell lines.
Amplification and overexpression of some proto-onco-
genes, such as c-raf, c-myc (Ikeda et al., 1989), and c-fos (Wu
et al., 1990) have been observed in some human osteosar-
comas. Similarly, c-myc was amplified in 30% of radiation-
induced murine osteosarcomas (Schon et al., 1986; Sturm et
al., 1990). The importance of tumour suppressor genes in the
development of experimental osteosarcomas is not known at
the present time.
This study presents an analysis of both known tumour
suppressor genes in a murine model of osteosarcoma. The
p53 gene was found rearranged and inactive in this tumour.
Similar changes were also found in several human osteosar-
coma cell lines. Both human and murine osteosarcomas show
alterations in the first intron of the p53 gene. This defect
causes the absence of p53 expression in the cells. The occur-
rence of analogous changes in human and mouse osteosar-
comas suggest that this alteration could contribute to the
development of the disease.
Materials and methods
Animals and tumours
The C3H mouse osteosarcoma (C3HOS) was established and
made available to us by Robert Sedlacek of the Massa-
chusetts General Hospital (MGH). The tumour was induced
with a single dose of 5000 rad to the leg of a C3H/F/Sed
mouse (Choi et al., 1979). Early passages of the original
tumour were inoculated s.c. into C3H/F/Sed mice (Depart-
ment of Radiology, MGH) and converted into cell cultures.
Subsequently, several clones (F6, BlO, G8, and C7) with
differing growth and differentiation properties were isolated.
The F6 and B10 clones were chosen for detailed characterisa-
tion as high and low differentiated variants, respectively.
These were established as transplantation lines, maintained
and passaged every 4-6 weeks in syngeneic mice. Tissue
culture lines were also simultaneously maintained. MC3T3-
El, an established murine osteoblast cell line (Kodama et al.,
1981), and liver tissue from a C3H mouse were used as
controls for RNA and DNA analyses.
Human cell lines
Human osteosarcoma cell lines, HOS, MG-63, U-20S, Saos-
2, G-292, human IMR90 lung fibroblasts, GM131 lympho-
blastoid cell line and Y79 retinoblastoma, were all obtained
from American Type Culture Collection (ATCC).
Histologic analysis
Representative tissue samples of murine tumours were fixed
in perfix and stained with haematoxylin and eosin.
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DNA and RNA preparation a
High molecular weight DNA from osteosarcoma and normal
tissues and cells was prepared by means of the phenol
method as previously described (Chandar et al., 1987). Ali-
quots of DNA were digested with appropriate restriction
enzymes, separated on 1% agarose gels, transferred onto
Nytran membranes and hybridised. Total RNA was ex-
tracted from cells and tissues by the method of Chomczynski
and Sacchi (1987). Aliquots of RNA were denatured with
6.3% formaldehyde and 50% formamide, then size-frac-
tionated on a 1.2% agarose gel containing 6.6% formal-
dehyde and, finally, blotted onto nytran membranes. Poly A
RNA was prepared by passing the total RNA through oligo
dT cellulose columns.
Probes
The 2.5 kb BamH1 fragment of the human pHp53B cDNA
(ATCC) was used for analysis of the p53 gene and its expres-
sion. This fragment contains 135 bp upstream of the first
ATG, the entire coding sequence and the untranslated 3'
sequences. This probe hybridised to exons 2- 11 of the mouse
p53 gene. The plasmid pMSVp53G, which contains the full
length murine gene (Eliyahu et al., 1984), was used for
structural analysis of the mouse p53 gene. For analysis of the
5' end of the gene a 0.73 kb HindIII/ECoRl fragment was
excised from pMSVp53G and cloned into a puc 19 vector.
For analysis of the human first exon we used plasmid pBT53
(Lamb & Crawford, 1986). The p 4.7R human Rb cDNA
(Friend et al., 1987) was cut to release the 3.8 and 0.6 kb
segments to study the 3' and 5' regions of the gene, respec-
tively. The murine Rb cDNA (pmRblO2) (Bernards et al.,
1989) was employed for studies of the murine gene. The rat
P-actin (pR PA-1) was obtained from the laboratory of Dr
Lawrence Kedes and used as a control in RNA hybridisa-
tions. All inserts were labelled by random priming method
(Feinberg & Vogelstein, 1983).
Hybridisation
The hybridisation and washing were performed under
high stringency conditions using 50% formamide, 5 x SSC,
5 x Denhardt's solution, 0.02 M phosphate buffer, and
50 mgml-' carrier DNA at 42°C. Wherever human probes
were used for analysis of mouse DNA, the hybridisations
were carried out at 37°C.
Densitometric measurements
Measurements of autoradiographs were carried out using a
Molecular Dynamics computing densitometer.
Results
Rearrangement ofp53 gene in murine osteosarcoma
The C3HOS radiation-induced osteosarcoma was converted
into a permanent culture line and subsequently cloned in our
laboratory (see methods). Two tumourigenic clones, BI0 and
F6, were chosen for further analysis. Upon inoculation into
C3H/F/Sed animals, F6 produces highly differentiated osteo-
sarcomas containing abundant calcified osteoid, while the
BI0 clone produces poorly differentiated tumours with mini-
mal calcification. Figure 1 shows the histological appearance
of the two tumours obtained 4-6 weeks after subcutaneous
injection of I x 106 cells.
The structure of the p53 gene was examined in the
DNA samples obtained from the F6 and B1O tumours, and
MC3T3-E1 osteoblast cells. The MC3T3-E1 cells were de-
rived from a C57 mouse, but no DNA polymorphisms have
been associated with the chromosomal region under study
(Zakut-Houri et al., 1983). Digestion of the control DNA
specimens with EcoRl generated a 16 kb fragment containing
b
Figure 1 Histology (haematoxylin and eosin) of the mouse
C3HOS tumour. a, Clone F6 is a well differentiated variant
presenting abundant osteoid; b, clone B10 resembles
undifferentiated soft tissue sarcoma with little osteoid.
the functional p53 gene and a 3.3 kb fragment containing the
pseudogene (Zakut-Houri et al., 1983) (Figure 2). Both F6
and B10 tumour DNA retained an intact pseudogene but
contained a truncated 13 kb p53 gene. Faint traces of a 16 kb
fragment appearing on Southern blots of tumour DNA are
of stromal origin. This was confirmed when cultured F6 and
B10 cells were used in place of tumour tissue. In such
preparations only rearranged bands are detected, as evi-
denced in BamHl digests shown in Figure 2. Other restric-
tion enzymes were employed in efforts to produce fragments
that cut within the p53 gene. The enzymes, HindlII and
BamH1, cut in the 6.1 kb first intron region as well as at
other sites of the gene (Figure 2). Other enzymes, Sac-I,
Kpn-I and Pst-I also cut within this region (Bienz et al., 1984)
and were therefore employed. BamHl digestion gave 10.5
(pseudogene) and 6.0 kb bands in normal DNA. Part of the
first intron and exons 2-6 of the p53 gene are contained
within the 6.0 kb fragment. This fragment appeared as a
7.5 kb band in the tumours. Similar results were observed
with HindlIl. Data obtained with other restriction enzymes
are shown in Table I. Digestions of control and tumour
DNA with Sac-I or Pst-I produced normal band patterns. In
contrast, Kpn-I digestion of DNA from F6 and BlO tumours
gave a 6.0 kb band in place of a 4.5 kb fragment obtained
from control cells (Table I). It appeared that the rearrange-
ment occurred 5' to the second exon and is located within the
intron. The p53 gene was similarly analysed in the original
primary tumour as well as the other cell clones. In all cases,
the rearrangements within the p53 gene were identical to
those described for F6 and BlO tumours (data not shown).
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Figure 2 The analysis of the p53 gene in mouse osteosarcoma. High molecular DNA from solid tumours and/or cultured cells was
digested with indicated restriction enzymes and hybridised to the cDNA probe php53B. A map of murine p53 gene shows the
restriction enzyme sites on the gene. (Bienz et al., 1984).
Table I p53 restriction fragments in normal and transformed cells
Size ofrestrictionfragments (kb)
Cell line/tumour P53 producer Sac-i Pst-J Kpn-l
MC3T3-E1 + 13.5, 5.0, 2.5, 0.6 3.0, 1.4, 1.2, 0.4 11, 4.5, 2.3, 1.25
C3HF6 tumour 13.5, 5.0, 2.5, 0.6 3.0, 1.4, 1.2, 0.4 11, 6.0, 2.3, 1.25
C3HB10 tumour - 13.5, 5.0, 2.5, 0.6 3.0, 1.4, 1.2, 0.4 11, 6.0, 2.3, 1.25
Southern Blot analysis was performed as described under Methods and hybridised to the
cDNA probe php53B. Values represent the approximate size ofhybridising DNA fragments
obtainedwithrespectiverestriction enzyme. Thefragment sizes werecalculatedbycomparing
their relative migrations with that of HindlIl digested 1 DNA and HaeIII digested 9X1I74
DNA.
alteration, we utilised genomic DNA probes to determine the
status of the non-coding first exon. The mouse probe specific
for the first exon when hybridised to the ECoRI-digested
DNA identified a novel 3.8 kb fragment, but did not bind to
the larger 13 kb fragment (Figure 3). In control tissue, this
probe bound to the 16 kb fragment. In Kpn-I digests a 6.0 kb
band was seen in place of a 5.2 kb band (Figure 3). The same
was true for the Sac-I digest. In normal tissue, Sac-I cuts at
sites in intron-I and 5' to exon-I yielding a 3.7 kb fragment.
In tumours, a fragment about 0.6 kb larger than normal was
obtained (data not shown). The above data demonstrate that
the rearrangement was contained within the first 3 kb of the
p53 first intron. The appearance of a novel fragment within
the ECoR1 digest, about 0.8 kb larger than the expected
length, suggested the presence of a sequence integrated within
the first intron region. Further characterisation of this region
will be required to confirm the nature of this integrated
sequence. The integrated DNA, however, did not seem to
markedly alter the region in its immediate vicinity and,
therefore, most other restriction sites appeared intact.
Northern analysis
The transcription of the p53 gene was analysed by means of
Northern analysis of total RNA isolated from tumour and
control cells. While a normal 2.0 kb transcript was present in
osteoblast cells, no message could be detected in the tumours
(Figure 4). In order to improve sensitivity, the poly A
mRNA was used in place of total RNA preparations. Five
.tg of poly A mRNA was run on a gel and blotted, but no
p53 message could be detected. All Northern blots were
rehybridised to P-actin for control and quantitative purposes
utilising a 2.2 kb P-actin message (Figure 4).
Structure ofp53 gene in human osteosarcomas
Five osteosarcoma cell lines that were available in our
laboratory were screened for structural and expression char-
acteristics of their p53 gene using ECORI and HindIII
digests. As seen from the map (Figure 5), ECORI cuts the
gene into two fragments, the smaller one carrying the first
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Figure 3 Analysis of p53 genomic DNA fragments detailing the
first exon region. DNA aliquots from MC3T3 E- 1 osteoblast
cells, an early passage of the C3HOS original tumour (C3H
tumour), BIO and G8 clones were digested with ECORI and
hybridised to a mouse p53 first exon specific probe. The same
analysis was also carried out in Kpn-I digested DNA.
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Figure 4 Expression of p53 gene in mouse osteosarcoma. Total
RNA was separated, blotted and hybridised to php53 a. The
same blot rehybridised to P
- actin b. Analysis with poly A -
RNA c.
Figure 5 a Southern analysis of p53 gene in human osteosarcoma
cells. Equal amounts of DNA from the various cell lines were cut
with ECOR1 or HindIII and hybridised to a human p53 cDNA
probe php53B. The same blot was rehybridised with a probe for
a - actin. b, Northern blot analysis of total RNA with php53B
probe for steady state message (upper panel). The same blot was
rehybridised to P - actin (lower panel).
exon region and a larger piece containing the rest of the
gene. This analysis provided us with information about the
status of the first exon as well. The status of the first exon
was also confirmed by rehybridising the blot with the human
first exon probe pBT53. This probe hybridised to a 3.7 kb
fragment in all cell lines (data not shown). For densitometric
measurement and to check variations in DNA concentra-
tions, the blot was also hybridised to a-actin. On hybridisa-
tion to the php53B probe, the expected bands (15.0 and
3.7 kb) were obtained in ECOR1 digests of the control cells.
However, the same analysis of cultured osteosarcoma cells
revealed notable differences. G-292 and MG-63 osteosarcoma
contains a 10 kb band in addition to the 15 kb band (Figure
5). Both of these cell lines (MG-63 and G-292), therefore,
seem to contain rearrangement in the first intron of the p53
gene, which is about 10 kb long in humans (Masuda et al.,
1987). A normal band pattern was seen with the HOS cell
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cell line although with an increased intensity, but densitomet-
ric measurements did not reveal any significant amplification
of the gene. Saos-2 lost most of the gene, with the exception
of the first exon, as documented by its hybridisation to the
3.7 kb band. This finding was interesting, as it suggested that
the deletion was not random but had occurred in the intron
region. Of all osteosarcomas tested, only U-20S cells present-
ed a normal hybridising pattern, although much weaker in its
intensity, as determined by densitometry. Similar analyses
were conducted with HindIII digests, which resulted in two
bands of 7.0 and 2.5 kb (Figure 5a), both of which represent
fragments originating from the middle and 3' end of the gene
and, therefore, not informative for alterations in the first
intron region. Decreased hybridisation was documented for
MG-63 and U-20S cells. Densitometry confirmed that MG-
63 contained only one allele which was rearranged, while
U-20S had only one allele which appeared structurally
intact. Saos-2 cells showed no p53 probe hybridising bands
(Figure 5a).
Northern analysis ofhuman p53 gene
p53 was transcribed into a 2.3 kb message in all control
tissues (Figure Sb). Most of the osteosarcoma cell lines do
not contain any transcript (G-292, Saos-2, and MG-63), and
only HOS cells showed increased levels of p53 message. Even
though U-20S had only one allele for p53, it appeared to
make normal amounts of the p53 transcript (Figure Sb).
Analysis ofRb gene in osteosarcoma
We screened for changes within the Rb gene in human
osteosarcoma cell lines, as well as in the mouse tumour to
determine if inactivation of Rb was a common event in these
tumours. No gross alterations were visible on Southern blots
in the DNA from the murine C3HOS tumours (Figure 6).
The presence of a normal 4.7 kb transcript could be detected
in the osteoblast cell line MC3T3-El, as well as in tumours.
A similar analysis was conducted with human osteosarcoma
cell lines. The 3.8 and 0.6 kb Rb gene specific probes span a
large region of the Rb gene and bind to several sequences on
HindIII digests as depicted in Figure 7. In HindIII digests,
deletion of the 3' end of the Saos-2 gene was evident. U-20S
showed decreased hybridisation to these probes, but no
quantitative differences were found. The latter alterations
were confirmed with ECORl digests (not shown). Hybridisa-
tion of the 0.6 kb probe to HindII digest showed that 14.0,
7.0, 6.0, 1.5, and 1.2 kb fragments were present in all the
osteosarcoma cell lines tested. U-20S cells are likely to con-
tain only one intact allele as judged by decreased hybridisa-
tion. In the Y79 retinoblastoma cell line, the 7.0 kb band was
absent. Northern analysis was performed with the 3.8 kb
probe and 4.7 kb transcripts could be detected in all cell
lines, with the exception of the Saos-2 and Y79 cell lines
(data not shown).
Analysis ofc-myc in the murine tumour
We also attempted to determine whether C3HOS contained
tumour alterations in c-myc, as this has been a consistent
observation in murine osteosarcoma tumours (Sturm et al.,
1990). Assays were conducted to uncover alterations in c-myc
gene structure and expression. ECOR1 digests of normal and
tumour DNA gave a 20 kb band for c-myc gene in all the
samples analysed and expression of normal levels of a 2.2 kb
RNA transcript was observed (data not shown).
Discussion
A large array of mutations affecting the p53 gene have been
identified and are thought to play a role in the transforma-
tion of not only skeletal, but also many other types of cells
(Levine et al., 1991; Hollstein et al., 1991). Our data are in
agreement with the results of Masuda et al. (1987) and
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Figure 6 The Rb gene in mouse osteosarcoma. a, High mole-
cular weight DNA from C3H mouse liver (control), C3HOS, F6
and B1O tumours was digested with HindlII, electrophoresed and
blotted. Hybridisations were done with a murine Rb cDNA
probe pRB102. b, Northern analysis of Rb gene expression. Total
RNA isolated and blotted as described in text was hybridised to
the probe pRB102.
Mulligan et al. (1990) and indicate that inactivation of p53 is
a common event in osteosarcoma development. The exact
role of the p53 gene either in the transformation process, or
in normal functions of bone cells is not known. The rear-
rangement identified in the C3HOS murine osteosarcoma
involves the first intron. Interestingly, the same lesion was
found in three out of five human tumour cell lines. In
comparing the two anti-oncogenes, the structural rearrange-
ment of the p53 gene is more prevalent than similar aberra-
tions of the Rb gene in the cell lines studied. Four of the five
human osteosarcoma cell lines showed aberrant expression of
p53. Among these, MG-63 and G-292 show gene rearrange-
ment in the first intron, while Saos-2 retained only the region
harbouring first exon and lost the rest of the gene. It is
therefore possible that an alteration in the first intron was
responsible for the resultant changes in Saos-2 cells. Re-
arrangement of the p53 gene in osteosarcoma cell lines has
been previously observed, and our data on MG-63 generally
agree with the published reports (Masuda et al., 1987; Miller
et al., 1990). Our data concerning p53 expression in G-292
are in agreement with observations by Diller et al. (1990), but
differ from those reported by Miller et al. (1990), who
reported synthesis of p53 RNA in these cells. It is not clear
why there is a discrepancy regarding the expression of p53 in
G292. HOS is known to harbour a point mutation within the
p53 coding sequence and overproduces a mutant p53 product
(Romano et al., 1989).
The rearrangement ofp53 in murine C3HOS osteosarcoma
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Figure 7 Rb gene in human osteosarcoma cell lines. High molecular weight DNA was cut with HindII and blotted and hybridised
to Rb probes (a & b). Two human RB probes spanning the whole gene, p3.8 and p0.6 were used for analysis of the whole gene and
are indicated at the bottom of the figure with the HindIII fragments they bind to (c).
is present in the original radiation-induced tumour, as well as
its clonal derivatives. The clones produce tumours with
different growth rates and properties upon injection into
animals. The rearrangement within the p53 gene has not
changed over many generations both in vitro and in vivo. This
indicates the importance of the described p53 aberration for
the maintenance of the tumourigenic state. This is further
supported by a recent study of primary osteosarcomas where
18% of the tumours that had rearranged p53 genes, had the
alteration mapping to the first intron region (Miller et al.,
1990). The inactivation of p53 via alteration within the first
intron thus appears to be unique to osteosarcoma and
different from other human cancers where p53 inactivation
occurs primarily by a loss of alleles and/or point mutations.
This does not, however, preclude the occurrence of other
mutations. In fact, in a recent study of sarcomas, gross
alterations in p53 with lack ofexpression, or aberrant expres-
sion of p53 were detected at high frequency in osteosarcoma
and rhabdomyosarcoma (Mulligan et al., 1990). Irrespective
of the mechanism, the alteration of normal p53 function has
an important role in neoplasia.
Gross rearrangements of p53 have been reported in virus-
infected erythroleukaemia cells (Mowat et al., 1985; Munroe
et al., 1990), as well as in Ab-MuLv transformed lymphoid
cells (Wolf & Rotter, 1984). In the latter case, the inactiva-
tion of the gene is a result of an insertion of the Mo-MuLV-
like DNA sequences into the first intron of the active gene in
these cells (Wolf & Rotter, 1984). These modifications appear
analogous to those seen in osteosarcomas and may reflect a
common pathway for tumour initiation from multipotent
precursor cells. Alternately, its similarity to virus-induced
alterations suggest that activation ofendogenous retroviruses
that frequently occur in radiation-induced tumours may have
a role in the induction of the murine tumour (Schmidt et al.,
1988).
Amplification of the c-myc gene has been reported in 30%
of the murine osteosarcomas tested (Strum et al., 1990). We
did not see amplification of c-myc in the C3HOS tumour or
the human osteosarcoma cell lines. The absence of the
oncogene amplification phenomenon could be due to the fact
that this change is a progression-related event, not directly
involving the carcinogenic process.
Our studies showed that structural rearrangements of Rb
antioncogenes may not be prevalent in human osteosarcoma,
since only one out of five cell lines showed gross alteration of
the Rb gene. The Rb gene in the mouse tumour also appears
intact and synthesises a normal 4.7 kb transcript. However,
given the large size of the gene and the wide variety of ways
that the Rb gene can be inactivated (Cavenee, 1991), our
data cannot exclude the involvement of Rb in neoplastic
transformation of cells under study. Nevertheless, the
analyses of Rb protein have been carried out in the same
osteosarcoma cell lines we examined and have appeared nor-
mal (Shew et al., 1989).
A large amount of data have been accumulated concerning
the various p53 mutations in human cancers (Levine et al.,
1991; Hollstein et al., 1991). Functionally, p53 appears simi-
lar to the retinoblastoma gene (Levine et al., 1991). It,
therefore, seems reasonable to suggest that the tumourigenic
process may require inactivation of either one of the genes.
Alternatively, if p53 and Rb antioncogenes form a part of
the cellular interactive regulatory mechanism, inactivation of
one may, in effect, lead to inactivation of the other. Intron
functions of several genes in transgenic mice have been tested
(Brinster et al., 1988), and were found to increase the trans-
criptional efficiency of genes introduced into mice. This
observation has also been extended to include the p53 gene
(Lozano et al., 1991). Studies are in progress to determine the
nature of alteration in the first intron of the human and
murine osteosarcoma p53 genes.
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